• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Science Washington Institute Recognizes ProfoundBio Co-Founders with 2024 Entrepreneurial Achievement Award

    10/11/24 9:30:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email

    ProfoundBio co-founders Dr. Baiteng Zhao and Dr. Tae H. Han recognized for building the state's most valuable life science company in less than a decade

    Life Science Washington Institute (LSWI), a Life Science Washington affiliate focused on supporting early-stage companies and entrepreneurs in Washington state, today announced Baiteng Zhao, PhD, and Tae H. Han, PhD, co-founders of ProfoundBio, as the recipients of the 2024 Entrepreneurial Achievement Award. Launched in 2020, this award honors founding leaders who have demonstrated significant entrepreneurial accomplishments, advanced life-changing innovations, and contributed to Washington state's economic development.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241011784140/en/

    Dr. Baiteng Zhao and Dr. Tae H. Han receives the 2024 Entrepreneurial Achievement Award (Photo: Business Wire)

    Dr. Baiteng Zhao and Dr. Tae H. Han receives the 2024 Entrepreneurial Achievement Award (Photo: Business Wire)

    LSWI is honoring Dr. Zhao and Dr. Han for their significant contributions to advancing life science innovations. Following their tenure at another homegrown Washington company, Seagen (now Pfizer), Dr. Zhao and Dr. Han co-founded ProfoundBio to provide better therapeutic options for patients with cancer. The ProfoundBio pipeline focused on potential best-in-class antibody-drug conjugates (ADCs), a cutting-edge technology that aims to eradicate cancer while sparing normal tissues. In just four years after its Series Pre-A financing, the ProfoundBio team advanced multiple ADC candidates into clinical trials and secured funding totaling $250 million, including an over-subscribed $112 million Series B round in February 2024 that was supported by many of the world's top life science investors. ProfoundBio was ultimately acquired by Danish drugmaker Genmab A/S (NASDAQ:GMAB) for approximately $1.8 billion in cash, one of the top life science deals in 2024.

    "ProfoundBio, founded and led by Baiteng Zhao and Tae Han, had nothing short of an astounding year and we are thrilled to recognize them as the winner of this year's Entrepreneurial Achievement award," said Richard Giersch, Executive Director of Life Science Washington Institute. "ProfoundBio is a powerful example of how Washington's life sciences ecosystem continues to thrive as talented leaders remain in the region, build new companies, and drive innovation. The company was able to develop such strong investor interest and ultimately be acquired because of its innovative proprietary technology platforms and a robust pipeline of drug candidates. This team is incredibly deserving of this award for their scientific and entrepreneurial accomplishments."

    Dr. Zhao and Dr. Han are proud graduates of LSWI's Washington Innovation Network (WIN) mentoring program, participating from 2019-2020. Celebrating 10 years of impact this year, WIN has had 102 ventures participate, with 43 graduates collectively raising over $3.2 billion. The program leverages Washington state's dynamic mix of seasoned entrepreneurs and industry leaders, connecting early-stage companies with the expert resources, people, and funding they need to drive life sciences innovation forward.

    The ProfoundBio journey exemplifies the power of the WIN program and highlights how Washington's life sciences ecosystem continues to thrive. By fostering homegrown talent and innovation, WIN plays a key role in ensuring Washington remains a top 10 life sciences hub.

    "We're honored to receive this year's Entrepreneurial Achievement Award and accept it on behalf of the ProfoundBio team. We are now a part of the inspiring group of award winners, all of us with a common vision and commitment to improving patient lives," said Dr. Zhao and Dr. Han. "Seattle is a special place to grow companies like ProfoundBio. We have a collaborative ecosystem, top talent, and supportive programs that help entrepreneurs bring lifesaving medicines to patients faster. In addition, we are grateful for the WIN program as it helped us during the initial phase of the company to be sure ProfoundBio was being built the right way for success. We look forward to seeing and contributing to the next chapter of life sciences innovation here in Washington state."

    Hear more from ProfoundBio and other WIN participants in a Life Science Washington Institute video:

    https://vimeo.com/873842986.

    About Life Science Washington Institute

    Life Science Washington Institute, "Where Entrepreneurs Come First," is driven by a mission of three closely connected goals: to launch life sciences companies, mentor entrepreneurs, and connect companies and entrepreneurs to resources they need. It is an essential part of Washington state's energetic and connected life sciences ecosystem, and it works to ensure life sciences entrepreneurs and companies have access to the right resources at the right time as they are founded and grown. For more information, visit https://www.lswinstitute.org/.

    About Life Science Washington

    Life Science Washington connects its 500+ members to each other and to funding, talent, partners and essential business services and elevates the industry by promoting policies that strengthen the environment for ground-breaking research and product development that improves and saves lives. For more information, visit https://lifesciencewa.org/.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241011784140/en/

    Get the next $GMAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    3/27/2026$32.00Outperform
    Wolfe Research
    3/2/2026$40.00Overweight
    Wells Fargo
    2/17/2026$41.50Buy
    Jefferies
    2/17/2026$34.00Equal-Weight
    Morgan Stanley
    9/23/2025$43.00Neutral → Buy
    Guggenheim
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $GMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Genmab with a new price target

    Wolfe Research initiated coverage of Genmab with a rating of Outperform and set a new price target of $32.00

    3/27/26 8:48:55 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Genmab with a new price target

    Wells Fargo initiated coverage of Genmab with a rating of Overweight and set a new price target of $40.00

    3/2/26 9:07:48 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Genmab with a new price target

    Jefferies resumed coverage of Genmab with a rating of Buy and set a new price target of $41.50

    2/17/26 8:18:22 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Major Shareholder Announcement

    Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 27, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,205,763 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S.   The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people

    3/30/26 11:59:55 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Publishes 2025 Annual Report

    Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2025 today, February 17, 2026 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email w

    2/17/26 11:01:23 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

    Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary  VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This regulatory surge signals deep institutional confidence in late-stage platforms capable of commercial conversion. The trend accelerated in January 2026 as Big Pharma intensified its race to acquire assets ahead of a $170 billion patent cliff[2]. Acquirers are now bypassing early-stage speculation to secure validated Phase 3 data and manufacturing infrastructure. This structural shift has directed institutional focus toward Oncolytic

    1/30/26 10:36:00 AM ET
    $ABBV
    $ADCT
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    SEC Filings

    View All

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    4/1/26 3:21:21 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    4/1/26 2:44:33 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    3/30/26 5:29:17 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Genmab A/S bought $102,411,048 worth of shares (1,055,784 units at $97.00) (SEC Form 4)

    4 - GENMAB A/S (0001434265) (Reporting)

    12/30/25 5:41:44 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Genmab A/S claimed ownership of 71,463,077 shares (SEC Form 3)

    3 - GENMAB A/S (0001434265) (Reporting)

    12/18/25 5:49:12 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Genmab A/S bought $102,411,048 worth of shares (1,055,784 units at $97.00) (SEC Form 4)

    4 - GENMAB A/S (0001434265) (Reporting)

    12/30/25 5:41:44 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

    Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

    2/22/21 8:00:51 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/8/24 10:03:08 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/2/24 2:18:06 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genmab A/S

    SC 13G - GENMAB A/S (0001434265) (Subject)

    2/6/23 2:36:15 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Financials

    Live finance-specific insights

    View All

    Genmab Publishes 2025 Annual Report

    Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2025 today, February 17, 2026 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email w

    2/17/26 11:01:23 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care